Elevated expression of HMGA1 and HMGA2 proteins is correlated with a highly malignant phenotype in several human tumors. We previously demonstrated that the block of HMGA2 protein synthesis prevented rat thyroid cell transformation by murine retroviruses. Suppression of HMGA2 synthesis was associated with lack of induction of HMGA1 proteins suggesting that both HMGA1 and HMGA2 play a role in the process of neoplastic transformation. To determine the role of the HMGA1 gene in thyroid cell transformation, we blocked HMGA1 protein synthesis by an antisense methodology. Here we report that transfection of an HMGA1 cDNA antisense construct into a normal rat thyroid cell line (FRTL-5 Cl2), followed by infection with Kirsten murine sarcoma virus (KiMSV), generated a transformed cell line that expresses high levels of the v-ras-Ki oncogene and that does not require thyroid-stimulating hormones for growth. However, this cell line does not show the malignant phenotype, i.e., it neither grows in soft agar nor induces tumors after injection in athymic mice. Moreover, the lack of the neoplastic phenotype in the virus-infected thyroid cells carrying the HMGA1 antisense construct correlates with the absence of induction of AP-1 transcriptional activity.
Introduction
The mammalian high mobility group 1 (HMGA1) family of chromosomal proteins is constituted by HMGA1a and HMGA1b, which are both encoded by the HMGA1 gene through alternative splicing (Johnson et al., 1989) , and the closely related HMGA2 protein (Man®oletti et al., 1991) . HMGA1 and HMGA2 are involved in the regulation of chromatin structure and function (Lovell-Badge, 1995) . While not typical transcriptional activators, HMGA proteins are required for the expression of many eucaryotic genes. These proteins bind adenine and thymine-containing sequences located in the minor groove of DNA. Their DNA-binding domain is located in the N-terminal region of the protein and contains three short basic repeats, the so-called`AT-hooks'. HMGA1/DNAbinding sites have been identi®ed in many promoters (Bustin, 1999) .
HMGA1 expression is low or absent in normal adult tissues, whereas it is very abundant during embryonic development (Zhou et al., 1995; Chiappetta et al., 1996) ; HMGA1 overexpression is a common feature of malignant tumors. Indeed, in the 1980s elevated expression of HMGA protein was found to be associated with the acquisition of a highly malignant phenotype in rat thyroid transformed cells and in thyroid and skin experimental tumors (Giancotti et al., 1985 (Giancotti et al., , 1987 (Giancotti et al., , 1989 . Subsequently, HMGA1 proteins were detected in human thyroid (Chiappetta et al., 1995 (Chiappetta et al., , 1998 , colon Abe et al., 1999; Chiappetta et al., 2001) , prostate (Tamimi et al., 1993) , cervix (Bandiera et al., 1998) , ovarian (Masciullo et al., manuscript in preparation) and pancreatic (Abe et al., 2000) carcinomas, but not in normal counterpart tissues.
In an earlier study designed to determine whether overexpression of HMGA2 gene was important for tumorigenesis or consequent to cell transformation, we blocked HMGA2 expression by introducing an antisense HMGA2 cDNA expression construct into rat thyroid cells . When these cells were subsequently infected by myeloproliferative sarcoma virus (MPSV) and the Kirsten murine sarcoma virus (KiMSV) carrying the v-mos and v-rasKi oncogenes, respectively, they were not able to grow in soft agar or to form tumors when injected into athymic mice. Conversely, untransfected retrovirusinfected rat thyroid cells formed colonies in soft agar and were highly tumorigenic in athymic mice. Interestingly, HMGA1 proteins were not expressed in the infected cells in which HMGA2 expression was suppressed by the antisense construct. This raised the possibility that the block of cell transformation may be dependent also on the expression of HMGA1 proteins.
Interestingly, neoplastic transformation is associated with a remarkable increase in AP-1 activity, likely due to a drastic induction of fra1 expression (which is prevented by suppression of the HMGA2 gene product), in thyroid cell lines infected by retroviruses carrying the v-mos or the Ki-ras oncogene (Vallone et al., 1997) .
In a study to establish whether HMGA proteins are also required for in vivo thyroid carcinogenesis, mice carrying a disrupted HMGA2 gene were treated with radioactive iodine or crossed with transgenic mice carrying the E7 papilloma virus oncogene under the transcriptional control of the thyroglobulin gene promoter . The HMGA2-null mice developed thyroid carcinomas with the same frequency as wild-type mice without signi®cant macroscopic dierences. These results indicate that, unlike HMGA1, HMGA2 is not required for in vivo thyroid cell malignant transformation. This hypothesis is supported by the induction of programmed cell death in carcinoma cell lines derived from human thyroid, lung, colon, and breast cancers by an adenovirus carrying the HMGA1 gene in an antisense orientation (Scala et al., 2000) .
To determine the role of the HMGA1 gene in thyroid cell transformation, we transfected the FRTL-5 Cl 2 rat thyroid cell line with an HMGA1 antisense construct, and infected the transfected cells with KiMSV. The infected cells carrying the HMGA1 antisense construct did not show any marker of malignant transformation and or induction of HMGA1 protein expression. Equally, no AP-1 transcriptional activity was detected in these cells. Conversely, the KiMSV-infected thyroid cells transfected with the backbone vector were tumorigenic after injection into athymic mice, expressed abundant levels of HMGA1 proteins and showed AP-1 transcriptional activity.
Results

Transfection of thyroid cells with an antisense HMGA1 construct prevents the appearance of the malignant phenotype
We introduced an antisense construct of HMGA1 cDNA into normal FRTL-5 Cl 2 cells in an attempt to block HMGA1 protein synthesis. The construct ( Figure 1A ) was obtained by inserting the HMGA1 cDNA in the antisense orientation in the pCMV vector under the transcriptional control of the cytomegalovirus promoter (Melillo et al., 2001) . The pCMV vector also carried the gene for geneticin resistance. Geneticinresistant clones were isolated, and expression of the HMGA1 a-s construct was analysed by strand-speci®c RT ± PCR ( Figure 1B ). Three transfectants were selected according to their capability to express the transfected construct (FRTL-5 HMGA1 as Cl1, Cl2, Cl3) and were assayed for the expression of thyroid dierentiation markers. There were no dierences between normal FRTL-5 Cl2 and transfected cells with respect to parameters of growth and dierentiation (data not shown).
FRTL-5 HMGA1 a-s cell clones were then infected with KiMSV carrying the v-ras-Ki oncogene. This virus was chosen because it induces the full neoplastic phenotype in FRTL-5 cells Berlingieri et al., 1995) . The virally infected cells carrying the HMGA1 antisense construct (FRTL-5 HMGA1 a-s KiMSV) retained an epithelial morphology, a feature completely lost in the normal cells when infected with the same virus ( Figure 2A) .
The growth curve of FRTL-5 HMGA1 a-s expressing the HMGA1 antisense construct perfectly overlapped that of untransfected cells. Dierently, FRTL-5 HMGA1 a-s KiMSV-infected cells grew without the six growth factors ( Figure 2B ), although growth rate was lower versus the untransfected FRTL-5 Cl2 cells infected with KiMSV (FRTL-5 KiMSV). There were no dierences among the various homogeneous clones; therefore these results pertain to one representative clone.
The neoplastic phenotype was evaluated in dierent cell clones by the colony-forming assay in soft agar and by injecting 2610 6 cells into athymic mice. No tumors were induced after injection of the virally infected cells carrying the HMGA1 antisense construct even after 4 months, nor were these cells able to grow in soft agar. In contrast, the untransfected cells, when infected, showed a high colony-forming eciency in agar and induced subcutaneous tumors that appeared with a short latency period (1 or 2 weeks; Table 1 ).
Expression of the viral oncogene and of thyroid differentiated functions in HMGA1 antisense-transfected thyroid cells
To exclude the possibility that the prevention of thyroid cell transformation caused by the HMGA1 antisense construct was due to the lack of expression of viral oncogene in the cells carrying the construct, we measured the protein level of the v-ras-Ki oncogene in the KiMSV-infected cells carrying the HMGA1 antisense construct. Western blot analysis revealed no dierences in the expression level of the v-ras-Ki oncogene between normal and antisense-transfected FRTL-5 Cl2 cells when infected with KiMSV ( Figure  3A) . Expression of the thyroid-speci®c genes (thyroglobulin, PAX8 and TSH receptor) was also analysed. All these genes were switched o in all the infected cell lines except the TSH receptor whose expression was reduced in the FRTL-5 HMGA1 a-s KiMSV cell line ( Figure 3B ).
HMGA1 and HMGA2 gene expression in normal and infected FRTL-5 Cl2 cells
Western blot analysis of total proteins extracted from normal and infected cells was carried out with antibodies raised against HMGA1 and HMGA2 proteins. As shown in Figure 4A , HMGA1 proteins were not detected in normal rat thyroid cells; conversely, both proteins were expressed in FRTL-5 cells transformed by KiMSV. HMGA2 gene expression was analysed by RT ± PCR with primers speci®c to the rat HMGA2 sequence. An ampli®ed product was detected in all KiMSV-infected cells irrespective of HMGA1 gene expression ( Figure 4B ).
v-ras-Ki-mediated AP-1 induction is decreased in the absence of HMGA1 protein
We used electrophoretic mobility shift assay (EMSA) to investigate AP-1 binding in normal and infected cell lines either expressing or not expressing the HMGA1 antisense. In vitro binding to the collagenase TPA response element, TRE, (collTRE) AP-1 was dramatically increased in the v-ras-Ki transformed cells, as already reported, compared with FRTL-5 cells ( Figure  5A ). There was only a slight increase in the collTRE AP-1 complex in the FRTL-5 Cl2 infected cells carrying the HMGA1 antisense construct. As a control of the speci®city of the antisense eect we also examined AP-1 activity in the cell lines expressing the antisense HMGA1 gene, but not the retroviral oncogene. As expected, these cells had the same low level of AP-1 binding as the parental FRTL-5 Cl2 cells.
The binding activity in dierent nuclear extracts was normalized by using an oligonucleotide probe for the ubiquitous Sp1 transcription factor ( Figure 5A ).
AP-1 compositional changes in transformed thyroid cells
We determined the composition of the complexes detected by EMSA with antibody supershift analysis ( Figure 5B ). Because of the small amount of gelretarded complex formed by the FRTL-5 Cl 2 nuclear proteins, we used prolonged autoradiographic exposure. The AP-1 complex detected in the v-ras-Ki transformed cells was supershifted by the anti-Fra-1 antibodies, whereas there was only a partial supershift with the anti-JunB complex.
Overexpression of Fra-1 and JunB in the malignant thyroid cells, but not in the infected cells carrying the HMGA1 antisense construct
To characterize the regulatory changes associated with the dierent AP-1 compositions, we analysed the protein and mRNA concentrations of the individual AP-1 components. Western blot analysis ( Figure 6A) showed accumulation of the Fra-1 and JunB proteins in the malignant cells. Conversely, there was no Fra-1 and JunB expression in normal cells, and only weak expression in Figure 6B ) paralleled the protein data suggesting that regulation of Fra-1 and JunB protein levels occurs at the mRNA level.
Activity of AP-1 target genes in normal and transformed HMGA1a-s cell lines
We next examined the expression of two AP-1 target genes implicated in the transformed phenotype, i.e., two extracellular matrix-degrading proteases, type 1 Figures 7A and B, both genes were expressed in the v-ras-Ki transformed cells, whereas stromelysin was expressed, at a low level, only in the FRTL-5 HMGA1a-s KiMSV cells.
Discussion
HMGA proteins are overexpressed in many human tumors (Fedele et al., 2001b) . However, the role of these proteins in the process of carcinogenesis is unclear. In fact, we previously found that thyroid cells carrying the HMGA2 gene in an antisense orientation are not associated with the malignant phenotype . Moreover, mice carrying a disrupted HMGA2 gene develop thyroid carcinomas, on a par with wild-type mice, which raises the possibility that HMGA1 proteins, rather than HMGA2, may be required for thyroid cell transformation . These data prompted us to investigate the role of HMGA1 in thyroid cell neoplastic transformation by suppressing HMGA1 protein synthesis by an antisense methodology.
Here we report that the block of HMGA1 protein prevents thyroid cell transformation by KiMSV. This result strongly indicates that HMGA1 protein plays a crucial role and HMGA2 an accessory role in thyroid cell transformation. A substantial body of evidence supports the importance of HMGA1 for thyroid cell transformation: (a) increased expression of HMGA1b is associated with the malignant phenotype and with anchorage-independent cell growth in two experimental cell lines (Wood et al., 2000a) ; (b) rat 2 cells overexpressing HMGA1 form tumors with distant Proteins were extracted and separated by SDS-15% PAGE and transferred to Immobilon membranes. The Western blot was incubated with antibodies speci®c for the p21 ras protein and with horseradish peroxidase-conjugated secondary antibodies: the complexes were detected by enhanced chemiluminescence. As a control for equal loading, the blot was incubated with antibodies against the ubiquitous g-tubulin protein.
(B) Northern blot analysis of TG, rTSH and PAX-8 mRNA. Total RNA extracted from the indicated cell lines was separated by electrophoresis and transferred to nylon membranes. The ®lters were hybridized with the TG, rTSH and PAX-8 radiolabeled cDNAs, and then with a rat b-actin probe, as a control for RNA loading metastases in nude mice (Wood et al., 2000b; Reeves et al., 2001) ; (c) transgenic mice overexpressing HMGA1 develop pituitary adenomas (Fedele et al., 2002) and NK lymphomas (Baldassarre et al., 2001) . Interestingly, virally infected rat thyroid cells carrying the HMGA1 antisense construct expressed HMGA2 but not HMGA1 protein. Since both proteins were blocked in the thyroid cells carrying the HMGA2 as construct, it is reasonable to suggest that HMGA2 is able to control HMGA1 synthesis, but not vice versa.
Here, we con®rm that thyroid cell transformation is associated with induction of the AP-1 transcriptional complex, which is prevented by the block of HMGA1 synthesis. In particular, fra-1 gene induction is blocked in the absence of HMGA1. The molecular mechanism underlying this event is still to be determined, however the presence of ®ve consensus binding sites for members of the HMG-box family in the fra-1 promoter may account for the HMGA1-regulated fra-1 expression.
It is interesting that even though HMGA1 seems to be required for thyroid cell transformation, its overexpression in normal thyroid cells does not transform the cells but causes an earlier entry into S phase and a delay in the G2-M transition that results in apoptosis, probably due to the con¯ict between mitogenic pressure and the inability to proceed through the cell cycle (Fedele et al., 2001a) . The dierent cellular context may account for the dierent eects of HMGA1 overexpression.
The data described herein support the concept that HMGA1 protein is pivotal in the process of carcinogenesis. This issue might be addressed by induction of experimental carcinoma in mice carrying the HMGA1 gene disrupted in both alleles. However, this phenotype appears, at present, to be lethal during embryogenetic development (manuscript in preparation), thus the generation of conditional HMGA1-knock-out mice may give an answer.
In conclusion, suppression of HMGA1 protein function by antisense methodology or by drugs that impairs HMGA1 function may be envisaged as a novel treatment strategy for human malignant neoplasias. Given the dierential expression of HMGA1 in neoplastic and normal cells, such therapy would be highly speci®c and non-toxic. Moreover, since HMGA1 overexpression appears to be a general feature of human malignant neoplasms, treatment based on inhibition of HMGA1 function might be applicable to diverse types of cancer. 
Materials and methods
Cell cultures and viruses
FRTL-5 Cl2 rat thyroid cells are derived from 3 ± 4-week-old Fisher rats Ambesi-Impiombato et al., 1980) . They were grown in Coon's modi®ed Ham's F12 medium supplemented with 5% calf serum (Gibco Laboratories) and six growth factors (1610 710 M TSH, 10 mg/ml insulin, 1610 78 M hydrocortisone, 5 mg/ml human transferrin, 10 ng/ml somatostatin, 10 ng/ml glycil-L-histidil-L-lysine acetate). Infection with KiMSV was carried out as described previously , and cells were selected for their capability to grow without thyroid-stimulating hormones. All transfections were performed by the calcium phosphate procedure as described elsewhere (Graham and Van der Eb, 1973) , and geneticin-resistant clones were isolated.
Assay of the transformed state
Tumorigenicity of the cell lines was tested by injecting 2610 6 cells subcutaneously into athymic mice. Soft agar colony assays were performed as previously described (Macpherson and Montagnier, 1964) .
RNA extraction and Northern blot analysis
Total RNA was extracted using the RNAeasy kit (Qiagen). Northern blot hybridization was performed according to standard procedures (Sambrook et al., 1989) . All cDNA probes were radiolabeled with a random primes synthesis kit (Stratagene). Hybridization reactions were performed at 428C with 2610 6 c.p.m./ml of hybridization solution. After washes, ®lters were air-dried and exposed to autoradiographic ®lm for 1 ± 4 days. The probes used were: a 1.55-kb EcoRI fragment corresponding to the cDNA of the mouse junB gene (Ryder et al., 1988) ; a 1.5-kb EcoRI fragment corresponding to the cDNA of the rat fra-1 gene (Cohen and Curran, 1988) ; a 0.4-kb EcoRI-HindIII fragment corresponding to the cDNA of the human GAPDH (glyceraldehyde 3-phosphate dehydrogenase) control was used to assess equal RNA loading; a 680-bp EcoRI-PstI fragment corresponding to the 3' end of the rat thyroglobulin (TG) gene (Di Lauro et , 1982) ; the rTSH and the Pax-8 probes are described elsewhere (Berlingieri et al., 1990; Zannini et al., 1992) .
Reverse transcriptase-PCR analysis
Five micrograms of total RNA, digested with DNAse, were reverse transcribed using random hexonucleotides as primers (100 mM) and 12 units AMV reverse transcriptase (Promega); 0.2 mg of cDNA were ampli®ed in a 25-ml reaction mixture containing 0.2 mM dNTPs, 1.5 mM MgCl 2 , 0.4 mM of each primer, 1 unit Taq DNA polymerase (Perkin-Elmer). For the type 1 collagenase, after a ®rst denaturing step (958C for 2 min), PCR ampli®cation was performed for 30 cycles (958C for 1 min, 458C for 30 s, 728C for 30 s). The sequences of forward and reverse primers used for ampli®cation of speci®c cDNAs were: 5'-TTGGCGGGGACGCCCATTTTGAT-GATGA-3' and 5'-AGACAGCATCTACTTTGTCGCCA-ATTCCAGG-3' (nucleotides 570 ± 601 and 1259 ± 1290, respectively) (Gack et al., 1994) . Expression of the GAPDH gene was used as an internal control. The speci®c primers were: forward 5'-ACATGTTCCAATATGATTCC-3' and reverse 5'-TGGACTCCACGAC-GTACTCA-3' corresponding to the nucleotides 195 ± 215 and 355 ± 335, respectively (Tokunaga et al., 1987) . To detect endogenous HMGA2 gene expression, we used primers speci®c for exons 1 and 5 (forward: 5'-ATATAAGCTTGGTACCGGTAGAGGCAG-TGG-3'; reverse: 5'-ATATAAGC-TTACCCCGCAGGAAG-TAGAAAG-3') coding sequences. To ensure that RNA samples were not contaminated with DNA, negative controls were obtained by performing the PCR on samples that were not reverse-transcribed but otherwise identically processed.
Nuclear extract preparation
Cells were washed twice in phosphate-buered saline and resuspended in 10 volumes of a solution containing 10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM DTT (homogenization solution). The cells were disrupted by passage through a 26-gauge needle. Nuclei were collected by centrifugation at 1500 r.p.m. and resuspended in a 1.2-volume of extraction solution containing 10 mM HEPES pH 7.9, 0.4 M NaCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 0.5 mM DTT, 5% glycerol, to allow elution of nuclear proteins by gentle shaking at 48C. Nuclei were pelleted again by centrifugation at 12 000 r.p.m. and the supernatant was stored at 7708C until used. The protease inhibitors leupeptin (5 mM), aprotinin (1.5 mM), phenylethylsulfunil¯uoride (2 mM), peptastatin A (3 mM), and benzamidine (1 mM) were added to both homogenization and extraction solutions. Protein concentration was determined by the Bradford protein assay (BioRad).
Electrophoretic mobility shift assay
Nuclear extracts (2.5 ± 5 mg of proteins) were incubated in 20 mM HEPES pH 7.5, 40 mM KCl, 5% glycerol in a volume Figure 6 (A) Western blotting analysis of the AP-1 components in normal and infected cell lines. Nuclear proteins were extracted and separated by SDS ± PAGE and transferred to PVDF membranes. The ®lter was ®rst incubated with antibodies speci®c for Fra-1 and JunB proteins, and then with horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence. As a control for equal loading, the blot was incubated with antibodies against the g-tubulin protein. (B) Analysis of fra-1 and junB gene expression. Northern blot hybridization with the Fra-1 and JunB probes of total RNA from normal and transformed thyroid cell lines with or without the HMGA1 as construct. Ten micrograms of total RNA were loaded for each cell line of 20 ml containing 1 mg poly (dI-dC) and 5 mM spermidine, for 10 min at room temperature. Binding reactions were incubated for 15 min after addition of the probe. The sequences of the oligonucleotide probes were: AP-1 consensus TRE (coll TRE), derived from the human collagenase promoter (Lee et al., 1987) 5'-TTCCGGCTGACTCAT-CAAGCG-3'; Sp1 consensus binding sequence (Briggs et al., 1986) 5'-ATTCGATCGGGGCGGGGCGAGC-3'. Samples were then separated on 8% native polyacrylamide gels (acrylamide: bis 29 : 1 in 0.56TBE). For the antibody supershift analysis, the reactions were performed by preincubating nuclear extracts with 0.5 mg of antibody at 48C for a minimum of 3 h. After addition of the labeled oligonucleotide and 15 min incubation at room temperature, the products were resolved on 8% PAGE. The anti-JunB and anti-Fra-1 antibodies were purchased from Santa Cruz Biotechnology (USA).
